Long-term Efficacy of Perampanel in a Child with Dravet Syndrome

Eulàlia Turón-Viñas1, Asunción Díaz-Gómez1, Elisabet Coca1, Lucía Dougherty1, Carlos Ruiz1, and Susana Boronat1

Abstract
Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) mostly due to mutations in SCN1A gene. Perampanel is a selective and non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist. There is increasing experience in the use of perampanel in this syndrome; however, there is still a lack of evidence of sustained benefit years after the beginning of the treatment.

We report a twelve-year-old girl who was diagnosed with Dravet Syndrome when she was 2 years old and has been on perampanel since she was 7. Her genetic test showed a de novo previously described heterozygous SCN1A mutation in the 24th exon (c.4547C>A, p.Ser1516*). She received previous antiseizure drug combinations with little benefit. When perampanel was started, there was a complete resolution of her spontaneous seizures that has continued five years later. More studies are needed to investigate if there is an association between this excellent response and the genotype of our patient.

Keywords
Dravet Syndrome, perampanel, children, case report.

Introduction
Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) mostly due to mutations in SCN1A gene.1 Several antiseizure drugs (ASD) have been tested in patients with this syndrome, with only few of them showing some benefit. Previous reports have shown that the combination of valproate, clobazam and stiripentol are effective in reducing the frequency of seizures in patients diagnosed of Dravet syndrome.2 Ketogenic diet also reduces seizure frequency and duration in DEE.3 Recently, some new drugs, like cannabidiol, especially in addition to clobazam, and fenfluramine have proved to be also effective,4,5 although they are still not commercialised in some countries. Besides, there is still little evidence of perampanel benefits in Dravet Syndrome, especially long-term benefits. We present a patient with Dravet syndrome and excellent long-term response to perampanel.

Case
Our patient is a 12-year-old girl who was diagnosed of Dravet syndrome at 2 years of age. Her first seizures were bilateral tonic-clonic and occurred when she was 7 months old during a febrile illness. She later developed febrile generalized and unilateral seizures, and suffered two status epilepticus before she was 2 years old. At this age, she also presented with myoclonic seizures and monthly focal motor afebrile seizures. A psychomotor delay became evident at this age. Genetic test performed at 2 years of age revealed a de novo heterozygous SCN1A mutation in the 24th exon (c.4547C>A, p.Ser1516*), previously described as pathogenic in other patients with Dravet syndrome. Another mutation, found in SCN2A gene (c.1329A>C, p.Glu43Asp), was ruled out because it was inherited from her healthy mother.

From 2 to 6 years of age there was a dramatic increase in her seizure frequency. At school, she suffered from daily reflex myoclonic seizures triggered by fixation on patterns (plaid...
Dravet syndrome is a severe DEE characterized by multiple seizure types.\textsuperscript{1} It usually begins with complex febrile seizures in young infants with other types of seizures developing later, being myoclonic and hemiclonic seizures, obtundation status and reflex seizures the most typical ones. Mutations in the SCN1A gene are found in up to 80% of patients with Dravet syndrome. A genotype-phenotype relation has been proposed, by which truncating mutations, like the one found in our patient, could be found in patients with early onset of seizures and worse cognitive outcomes.\textsuperscript{6-9} SCN1A encodes the alpha-subunit of neuronal voltage gated sodium ion channel, type1 (NaV 1.1), which is primarily expressed in neuronal cells in the central nervous system.\textsuperscript{10} A loss of its function seems to affect inhibitory GABAergic pathways and lead to epilepsy.

Perampanel is a selective and noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist.\textsuperscript{11} The AMPA receptor is a subtype of glutamate receptor and plays a role in excitatory postsynaptic potentials.

Perampanel has proved to be effective in both focal and generalized seizures, and has been used in children and adolescents with refractory epilepsy. In some previous reports, few patients with Dravet syndrome were included\textsuperscript{12-17} but only 3 of these patients were under 7 years of age. Besides, follow-up on previous reports was no longer than 12 months; Chang demonstrates that, contrary to other etiologies, patients with Dravet syndrome who respond to perampanel remained stable up to 12 months after its initiation,\textsuperscript{12} but there is a lack of studies with longer follow-up.

Efficacy studies show that some patients can improve drastically with perampanel, even obtain a complete remission of their seizures, while other patients show no improvement or even deterioration.\textsuperscript{13} Besides, perampanel seems not to target a specific seizure type but to be effective in all seizure types, in a “all-or-nothing” fashion, when effective.\textsuperscript{13} The efficacy of perampanel has also been described as disease-specific in Dravet syndrome.\textsuperscript{12} An impaired GABA inhibition secondary to AMPA receptor-mediated excitotoxicity has been proved in Dravet syndrome, which leads to epilepsy development. In this situation, an AMPA antagonist may attenuate this impaired GABAergic transmission and therefore help control seizures. Besides, Ishikawa reported a newborn with an early myoclonic epilepsy with a SCN1A mutation with excellent response to perampanel, suggesting that this effect could be also SCN1A-mutation-specific.\textsuperscript{18} However, up to 33% of patients in the previous reports showed no benefit or even deterioration with perampanel in patients with mutations in SCN1A.\textsuperscript{12-17} More studies are needed to investigate if there is an association between the response to certain drugs as perampanel and the patient’s genotype.

Another interesting unanswered question is whether the efficacy in our patient, and also in previous reports, is due to perampanel alone or in combination to other ASD. Our patient was being treated with valproate and clobazam, suffering from frequent seizures, and she immediately experienced an excellent response after adding perampanel. Although there seems to be a clear relation to perampanel initiation, we cannot rule out a synergistic effect of the three drugs. Previous reports does not analyze the effect of perampanel on patients with Dravet syndrome in combination with other treatments.\textsuperscript{13,15}

To conclude, we present a 12-year-old patient with Dravet syndrome who has been under treatment with perampanel for the last 5 years with a complete control of her spontaneous seizures. To the best of our knowledge this is the longest follow-up of perampanel on Dravet syndrome reported to date.
Ethical Approval
Not applicable, because this article does not contain any studies with human or animal subjects.

Informed Consent
Not applicable, because this article does not contain any studies with human or animal subjects.

ORCID iD
Eulàlia Turón-Viñas https://orcid.org/0000-0001-6171-0282

Trial Registration
Not applicable, because this article does not contain any clinical trials.

References
1. Dravet C. The core dravet syndrome phenotype. Epilepsia. 2011;52(Suppl 2):3-9.
2. Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet Lond Engl. 2000;356(9242):1638-1642.
3. Caraballo RH, Cersósimo RO, Sakr D, Cresta A, Escobal N, Fejerman N. Ketogenic diet in patients with dravet syndrome. Epilepsia. 2005;46(9):1539-1544.
4. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. 2017;376(21):2011-2020.
5. Ceulemans B, Boel M, Leyssens K, et al. Successful use of fenfluramine as an add-on treatment for dravet syndrome. Epilepsia. 2012;53(7):1131-1139.
6. Ceulemans BPGM, Claes LRF, Lagae LG. Clinical correlations of mutations in the SCN1A gene: from febrile seizures to severe myoclonic epilepsy in infancy. Pediatr Neurol. 2004;30(4):236-243.
7. Marini C, Scheffer IE, Nabbout R, et al. The genetics of dravet syndrome. Epilepsia. 2011;52(Suppl 2):24-29.
8. Ishii A, Watkins JC, Chen D, Hirome S, Hammer MF. Clinical implications of SCN1A missense and truncation variants in a large Japanese cohort with dravet syndrome. Epilepsia. 2017;58(2):282-290.
9. Gertler TS, Calhoun J, Laux L. A single-center, retrospective analysis of genotype-phenotype correlations in children with dravet syndrome. Seizure. 2020;75:1-6.
10. Volkers L, Kahlig KM, Verbeek NE, et al. Nav 1.1 dysfunction in genetic epilepsy with febrile seizures-plus or dravet syndrome. Eur J Neurosci. 2011;34(8):1268-1275.
11. Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel; a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52(7):1331-1340.
12. Chang F-M, Fan P-C, Weng W-C, Chang C-H, Lee W-T. The efficacy of perampanel in young children with drug-resistant epilepsy. Seizure. 2020;75:82-86.
13. Yoshitomi S, Takahashi Y, Yamaguchi T, et al. Efficacy and tolerability of perampanel in pediatric patients with dravet syndrome. Epilepsy Res. 2019;154:34-38.
14. De Liso P, Vigevano F, Specchio N, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-an Italian observational multicenter study. Epilepsy Res. 2016;127:93-100.
15. Lin K-L, Lin J-J, Chou M-L, et al. Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: the first real-world evaluation in asian pediatric neurology clinics. Epilepsia Behav EB. 2018;85:188-194.
16. Swiderska N, Tan HJ, Rajai A, Silwal A, Desurkar A, Martland T. Effectiveness and tolerability of perampanel in children, adolescents and young adults with refractory epilepsy: a UK national multicentre study. Seizure - Eur J Epilepsy. 2017;52:63-70.
17. Biró A, Stephani U, Tarallo T, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. Neuropediatrics. 2015;46(2):110-116.
18. Ishikawa N, Tateishi Y, Tani H, et al. Successful treatment of intractable life-threatening seizures with perampanel in the first case of early myoclonic encephalopathy with a novel de novo SCN1A mutation. Seizure. 2019;71:20-23.